Balugrastim

Drug Profile

Balugrastim

Alternative Names: Albugranin; Albumin fused G-CSF; CG-10639; Egranli; G-CSF/albumin human - Teva; Long-acting Granulocyte Colony Stimulating Factor (G-CSF) - Teva; Neugranin; Pegfilgrastim biosimilar - Teva

Latest Information Update: 13 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Neutropenia

Most Recent Events

  • 01 Jan 2015 Teva terminates phase II trial in Neutropenia (Chemotherapy-induced, In children, In adolscents) in USA, Bulgaria, Hungary, Romania, Russia, Ukraine, Poland, Georgia, Czech Republic and Slovakia (NCT01940601) prior to enrolment initiation
  • 04 Nov 2014 Regulatory submission withdrawn for Neutropenia (Chemotherapy-induced) in European Union (SC)
  • 26 Sep 2014 Preregistration for Neutropenia (Chemotherapy-induced) in European Union before September 2014 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top